Influenza infection in human host: challenges in making a better influenza vaccine

References

• Palese P, Shaw ML. Orthomyxoviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. Vol. 2, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1647–1689.
   Google Scholar
• Alexander DJ, Brown IH. Recent zoonoses caused by influenza A viruses. Revue Scientifique et Technique (International Office of Epizootics). 2000;19(1):197–225.
   PubMed Web of Science ®Google Scholar
• Tong S, Zhu X, Li Y, et al., et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 2013;9(10):e1003657.
   PubMed Web of Science ®Google Scholar
• Rota PA, Wallis TR, Harmon MW, et al. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990;175(1):59–68.
   PubMed Web of Science ®Google Scholar
• Influenza (Seasonal). World Health Organization; 2014. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/.
   Google Scholar
• People at High Risk of Developing Flu–Related Complications. Centers for Disease Control and Prevention; 2014. Available from: http://www.cdc.gov/flu/about/disease/high_risk.htm.
   Google Scholar
• Punpanich W, Chotpitayasunondh T. A review on the clinical spectrum and natural history of human influenza. Int J Infect Dis. 2012;16(10):e714–23.
   PubMed Web of Science ®Google Scholar
• Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ 2013;347:f5061.
   Google Scholar
• Chow A, Ma S, Chew SK, et al. Influenza-associated deaths in tropical Singapore. Emerg Infect Diseases. 2006;12(1):114.
   PubMed Web of Science ®Google Scholar
• Finkelman BS, Viboud C, Grenfell BT, et al. Global patterns in seasonal activity of influenza A/H3N2, A/H1N1, and B from 1997 to 2005: viral coexistence and latitudinal gradients. PloS One. 2007;2(12):e1296.
   PubMed Web of Science ®Google Scholar
• Bloom-Feshbach K, Alonso WJ, Viboud C, et al. Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review. PloS One. 2013;8(2):e54445.
   PubMed Web of Science ®Google Scholar
• Lowen AC, Mubareka S, Palese P, et al. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog. 2007;3:1470–1476.
   PubMed Web of Science ®Google Scholar
• Shaman J, Kohn M. Absolute humidity modulates influenza survival, transmission, and seasonality. Proc Natl Acad Sci USA. 2009;106:3243–3248.
   PubMed Web of Science ®Google Scholar
• König R, Stertz S, Gao Q, et al. Human host factors required for influenza virus replication. Nature. 2010;463(7282):813–817.
   PubMed Web of Science ®Google Scholar
• Cannell JJ, Vieth R, Madronich S, et al. Epidemic influenza and vitamin D. Epidemiol Infect. 2006;134:1129–1140.
   PubMed Web of Science ®Google Scholar
• Lofgren E, Fefferman NH, Naumova EN, et al. Influenza seasonality: underlying causes and modeling theories. J Virol. 2007;81(11):5429–5436.
   PubMed Web of Science ®Google Scholar
• Sagripanti J-L, Lytle CD. Inactivation of influenza virus by solar radiation. J Photochem Photobiol B. 2007;83(5):1278–1282.
   Web of Science ®Google Scholar
• Tamerius J, Nelson MI, Alonso WJ, et al. Global influenza seasonality: reconciling patterns across temperate and tropical regions. Environ Health Perspect. 2011;119(4):439.
   PubMed Web of Science ®Google Scholar
• Chew FT, Doraisingham S, Lee BW, et al. Seasonal trends of viral respiratory tract infections in the tropics. Epidemiol Infect. 1998;121:121–128.
   PubMed Web of Science ®Google Scholar
• Moura FE, Perdigao AC, Siqueira MM. Seasonality of influenza in the tropics: a distinct pattern in northeastern Brazil. Am J Trop Med Hyg. 2009;81:180–183.
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nature Rev Immunol. 2014;14(5):315–328.
   PubMed Web of Science ®Google Scholar
• Pulendran B, Maddur MS, Innate immune sensing and response to influenza. Influenza Pathogenesis and Control. 2015;II:23–71. Springer International Publishing
   Google Scholar
• Boehme KW, Compton T. Innate sensing of viruses by toll-like receptors. J Virol. 2004;78(15):7867–7873.
   PubMed Web of Science ®Google Scholar
• Ramos I, Fernandez-Sesma A. Cell receptors for influenza a viruses and the innate immune response. Front Microbiol. 2012;3:117.
   Web of Science ®Google Scholar
• Kash JC, Tumpey TM, Swayne DE, et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature. 2006;443(7111):578–581.
   PubMed Web of Science ®Google Scholar
• Kobasa D, Jones SM, Feldmann F, et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature. 2007;445(7125):319–323.
   PubMed Web of Science ®Google Scholar
• Baskin CR, Bielefeldt-Ohmann H, Aicher LD, et al. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci. 2009;106(9):3455–3460.
   PubMed Web of Science ®Google Scholar
• Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res. 2011;162(1–2):19–30.
   PubMed Web of Science ®Google Scholar
• Braciale TJ, Sun J, Kim TS. Regulating the adaptive immune response to respiratory virus infection. Nature Rev Immunol. 2012;12(4):295–305.
   PubMed Web of Science ®Google Scholar
• Carragher DM, Kaminski DA, Randall TD, et al. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol. 2008;181(6):4168–4176.
   PubMed Web of Science ®Google Scholar
• LaMere MW, Moquin A, Kaminski DA, et al. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol. 2011;85(10):5027–5035.
   PubMed Web of Science ®Google Scholar
• Hale BG, Albrecht RA, García-Sastre A. Innate immune evasion strategies of influenza viruses. Future Microbiol. 2010;5(1):23–41.
   PubMed Web of Science ®Google Scholar
• Van De Sandt CE, Kreijtz JH, Rimmelzwaan GF. Evasion of influenza A viruses from innate and adaptive immune responses. Viruses. 2012;4(9):1438–1476.
   PubMed Web of Science ®Google Scholar
• Fernandez-Sesma A, Marukian S, Yuen T, et al. Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol. 2006;80:6295–6304. [PubMed: 16775317]
   PubMed Web of Science ®Google Scholar
• Mao H, Tu W, Lau YL, et al. Inhibition of human natural killer cell activity by influenza virions and hemagglutinin. J Virol. 2010;84(9):4148–4157.
   PubMed Web of Science ®Google Scholar
• Das SR, Puigbò P, Yewdell JW, et al. Glycosylation focuses sequence variation in the influenza A virus H1 hemagglutinin globular domain. PLoS Pathog. 2010;6(11):.e1001211.
   Web of Science ®Google Scholar
• Taubenberger JK, Kash JC. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host & Microbe. 2010;7(6):440–451.
   PubMed Web of Science ®Google Scholar
• Domingo E, Baranowski E, Escarmís C, et al. Quasispecies structure and persistence of RNA viruses. Emerg Infect Dis. 1998;4(4):521.
   PubMed Web of Science ®Google Scholar
• Lauring AS, Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 2010;6(7):e1001005.
   PubMed Web of Science ®Google Scholar
• Tate MD, Job ER, Reading PC, et al. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses. 2014;6(3):1294–1316.
   PubMed Web of Science ®Google Scholar
• Taubenberger JK, Morens DM. Influenza: the mother of all pandemics. Rev Biomed. 1918;2006;(17):69–79.
   Google Scholar
• Ma W, Kahn RE, Richt JA. The pig as a mixing vessel for influenza viruses: human and veterinary implications. J Mol Genet Med. 2009;3(1):158.
   Google Scholar
• Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198(7):962–970.
   PubMed Web of Science ®Google Scholar
• Kilbourne ED. Influenza pandemics of the 20th century. Emerg Infect Dis. 2006;12(1):9–14.
   PubMed Web of Science ®Google Scholar
• Berkhoff EG, De Wit E, Rimmelzwaan GF, et al. Functional constraints of influenza A virus epitopes limit escape from cytotoxic T lymphocytes. J Virol. 2005;79(17):11239–11246.
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin & Immunother. 2012;8(1):81–88.
   PubMed Web of Science ®Google Scholar
• Geeraedts F, Goutagny N, Huckriede A, et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog. 2008;4(8):e1000138.
   PubMed Web of Science ®Google Scholar
• Jeisy-Scott V, Kim JH, Sambhara S, et al. TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice. J Virol. 2012;86(20):10988–10998.
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Sokolow LZ, Olsen SJ, et al. Prevention and control of influenza with vaccines: recommendations of the advisory committee on immunization practices, United States, 2015–16 influenza season. Morb Mortal Wkly Rep. 2015;64(30):818–825.
   Web of Science ®Google Scholar
• Influenza. Ministry of Health Singapore. Available from: https://www.moh.gov.sg/content/moh_web/home/diseases_and_conditions/i/influenza.html.
   Google Scholar
• Gupta V, Dawood FS, Kheong CC, et al. Influenza vaccination guidelines and vaccine sales in southeast Asia: 2008–2011. PloS one. 2012;7(12):e52842.
   Google Scholar
• US Centers for Disease Control and Prevention. Seasonal influenza activity surveillance reports: 2001-2002 to 2014-2015 seasons; [cited 2015 Dec 17]. Available from: http://www.cdc.gov/flu/weekly/pastreports.htm
   Google Scholar
• World Health Organization. WHO/Europe influenza surveillance. [cited 2015 Dec 20]. Available from: http://www.euroflu.org/index.php
   Google Scholar
• Osterhaus A, Fouchier R, Rimmelzwaan G. Towards universal influenza vaccines? Philos Trans R Soc London [Biol]. 2011;366(1579):2766–2773.
   PubMed Web of Science ®Google Scholar
• Pica N, Palese P, Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Medicine. 2013;64:189–202.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang L, Compans R, et al. Universal influenza vaccines, a dream to be realized soon. Viruses. 2014;6(5):1974–1991.
   PubMed Web of Science ®Google Scholar
• Schotsaert M, Influenza Vaccines: G-SA. A moving interdisciplinary field. Viruses. 2014;6(10):3809–3826.
   PubMed Web of Science ®Google Scholar
• Sui J, Hwang WC, Wan H, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nature Struct Mol Biol. 2009;16(3):265–273.
   PubMed Web of Science ®Google Scholar
• Wang TT, Tan GS, Palese P, et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci. 2010;107(44):18979–18984.
   PubMed Web of Science ®Google Scholar
• Grebe KM, Yewdell JW, Bennink JR. Heterosubtypic immunity to influenza A virus: where do we stand? Microb Infect. 2008;10(9):1024–1029.
   PubMed Web of Science ®Google Scholar
• Soema PC, Van Riet E, Amorij JP, et al. Development of cross-protective influenza A vaccines based on cellular responses. Front Immunol. 2015;6:237.
   PubMed Web of Science ®Google Scholar
• Atsmon J, Kate-Ilovitz E, Ben-Yedidia T, et al. Safety and immunogenicity of multimeric-001—a novel universal influenza vaccine. J Clin Immunol. 2012;32(3):595–603.
   PubMed Web of Science ®Google Scholar
• Atsmon J, Caraco Y, Ben-Yedidia T, et al. Priming by a novel universal influenza vaccine (Multimeric-001)—A gateway for improving immune response in the elderly population. Vaccine. 2014;32(44):5816–5823.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Treanor JJ, Gorse GJ, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200(2):17–80.
   Web of Science ®Google Scholar
• Treanor JJ, Mattison HR, Dumyati G, et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med. 1992;117:625–633.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007;6(5):699–710.
   Google Scholar
• Lambe T. Novel viral vectored vaccines for the prevention of influenza. Mol Med. 2012;18(8):e60.
   Web of Science ®Google Scholar
• Warren HS, Chedid LA. Future prospects for vaccine adjuvants. CRC Crit Rev Immunol. 1986;4:369–388.
   Google Scholar
• Dormitzer PR, Galli G, Rappuoli R, et al. Influenza vaccine immunology. Immunol Rev. 2011;239(1):167–177.
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov. 2003 Sep 1;2(9):727–735.
   PubMed Web of Science ®Google Scholar
• Keitel WA, Atmar RL. Vaccines for pandemic influenza: summary of recent clinical trials. Vaccines for Pandemic Influenza. Curr Top Microbiol Immunol. 2009;333:431–451.
   Google Scholar
• Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw. 2015;15(2):51–57.
   PubMed Web of Science ®Google Scholar
• Wong -S-S, Webby RJ. Traditional and new influenza vaccines. Clin Microbiol Rev. 2013;26(3):476–492.
   PubMed Web of Science ®Google Scholar
• Treanor JJ, El Sahly H, Cox M, et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011;29:7733–7739.
   PubMed Web of Science ®Google Scholar
• Baxter R, Patriarca PA, Cox MM, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine. 2011;29:2272–2278.
   PubMed Web of Science ®Google Scholar
• King JC Jr, Cox MM, Patriarca P, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine. 2009;27:6589–6594.
   PubMed Web of Science ®Google Scholar
• Lopez-Macias C, Ferat-Osorio E, Glenn G, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebocontrolled trial of adults in Mexico. Vaccine. 2011;29:7826–7834.
   PubMed Web of Science ®Google Scholar
• Tripp RA, Tompkins SM. Virus-vectored influenza virus vaccines. Viruses. 2014;6(8):3055–3079.
   PubMed Web of Science ®Google Scholar
• Antrobus RD, Berthoud TK, Gilbert SC, et al. Coadministration of seasonal influenza vaccine and MVA-NP+ M1 simultaneously achieves potent humoral and cell-mediated responses. Mol Ther. 2014;22(1):233–238.
   PubMed Web of Science ®Google Scholar
• End-of-season influenza vaccine effectiveness estimates for the 2014-15 season: US Influenza Vaccine Effectiveness (Flu VE) Network. Available from: http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2015-06/flu-02-flannery.pdf.
   Google Scholar
• Russell CA, Jones TC, De Jong JC, et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine. 2008;26:D31–34.
   PubMed Web of Science ®Google Scholar
• Lapedes A, Farber R. The geometry of shape space: application to influenza. J Theor Biol. 2001;212(1):57–69.
   PubMed Web of Science ®Google Scholar
• Chen R, Holmes EC. Avian influenza virus exhibits rapid evolutionary dynamics. Mol Biol and Evol. 2006;23(12):2336–2341.
   PubMed Web of Science ®Google Scholar
• Bush RM, Bender CA, Fitch WM, et al. Predicting the evolution of human influenza A. Science. 1999;286:1921–1925.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Selecting vaccine strains for H3N2 human influenza A virus. Meta Gene. 2015;4:64–72.
   PubMedGoogle Scholar
• Xia Z, Jin G, Zhou R, et al. Using a mutual information-based site transition network to map the genetic evolution of influenza A/H3N2 virus. Bioinformatics. 2009;25(18):2309–2317.
   PubMed Web of Science ®Google Scholar
• He J, Deem MW. Low-dimensional clustering detects incipient dominant influenza strain clusters. Protein Eng Des Sel. 2010;23:935–946.
   PubMed Web of Science ®Google Scholar
• Suzuki Y. Predictability of antigenic evolution for H3N2 human influenza A virus. Genes Genet Syst. 2013;88:225–232.
   PubMed Web of Science ®Google Scholar
• Smith DJ, Lapedes AS, Fouchier RA, et al. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004;305(5682):371–376.
   PubMed Web of Science ®Google Scholar
• Ito K, Igarashi M, Takada A, et al. Gnarled-trunk evolutionary model of influenza a virus hemagglutinin. PLoS One. 2011;6(10):e25953.
   PubMed Web of Science ®Google Scholar
• Łuksza M, Lässig M. A predictive fitness model for influenza. Nature. 2014;507(7490):57–61.
   PubMed Web of Science ®Google Scholar
• Steinbrück L, Klingen TR, McHardy AC. Computational prediction of vaccine strains for human influenza A (H3N2) viruses. J Virol. 2014;88(20):12123–12132.
   PubMed Web of Science ®Google Scholar
• Gupta V, Earl DJ, Deem MW. Quantifying influenza vaccine efficacy and antigenic distance. Vaccine. 2006;24(18):3881–3888.
   PubMed Web of Science ®Google Scholar
• Vijaykrishna D, Holmes EC, Stockwell TB, et al. The contrasting phylodynamics of human influenza B viruses. Elife. 2015;4:e05055.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Jones M, Heneghan CJ, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. Bmj. 2014;348:g2545.
   PubMed Web of Science ®Google Scholar
• National Early Season Flu Vaccination Coverage, United States, November 2015. Centers for Disease Control and Prevention, 2015. Available from: http://www.cdc.gov/flu/fluvaxview/nifs-estimates-nov2015.htm.
   Google Scholar
• Palache A, Oriol-Mathieu V, Music T, et al. Seasonal influenza vaccine dose distribution in 157 countries (2004–2011). Vaccine. 2014;32(48):6369–6376.
   PubMed Web of Science ®Google Scholar
• Jalilian B, Christiansen SH, Vorup-Jensen T, et al. Properties and prospects of adjuvants in influenza vaccination-messy precipitates or blessed opportunities? Mol Cell Ther. 2013;1:2.
   PubMedGoogle Scholar
• Norton EB, Clements JD, Cárdenas-Freytag L, et al. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. J Virol. 2010;84(6):2983–2995.
   PubMed Web of Science ®Google Scholar
• Uchide N, Toyoda H. Antioxidant therapy as a potential approach to severe influenza-associated complications. Molecules. 2011;16(3):2032–2052.
   PubMed Web of Science ®Google Scholar